Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare Biotechnology
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select... see more

TSX:GUD - Post Discussion

Knight Therapeutics Inc > BRISTOL Myers squib discussing on CNBC its’ acquisition
View:
Post by GoldenInvestor on Jun 03, 2022 2:14pm

BRISTOL Myers squib discussing on CNBC its’ acquisition

Their focus on new innovative drugs and cell therapy, novel therapies amd cancer through Turning Point & focus on oncology.

Discussed challenge on manufacturing to keep up with demand.

Anyone know of a GUD manufacturing co?  In South America ...

CEO says it's early stages of therapies!!!

from GUD to great times ahead just from listening to industry pro's

GI

Comment by Chianchin on Jun 03, 2022 5:03pm
These clones aliases would like you to beleive and imply that GUD is developing new drugs. GUD is a re-seller of expired generics drugs in lATAM they sell these drugs at a huge discound and near impossible to make a profits guven worthless LATAM currencies. It is not a coincidence that the market values GUD at $5 only because GUD is the only few buyers left or it would be at $3
Knight Therapeutics Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities